Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 2
1996 3
1997 1
1999 2
2000 1
2002 2
2004 1
2005 2
2006 1
2007 2
2009 2
2011 1
2014 2
2015 1
2016 2
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma.
Villa D, Hoster E, Hermine O, Klapper W, Szymczyk M, Bosly A, Unterhalt M, Rimsza LM, Ramsower CA, Freeman CL, Scott DW, Gerrie AS, Savage KJ, Sehn LH, Dreyling M. Villa D, et al. Blood Adv. 2022 Sep 27;6(18):5285-5294. doi: 10.1182/bloodadvances.2022007371. Blood Adv. 2022. PMID: 35439293 Free PMC article. Clinical Trial.
The objective of this study was to explore differences in outcomes between first-line rituximab plus bendamustine (R-B) and R-CHOP/R-DHAP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, dexamethasone, cytarabine, cisplatin) in transplant-eligible patien …
The objective of this study was to explore differences in outcomes between first-line rituximab plus bendamustine (R-B) and R-CHOP/R- …
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis.
Fischer L, Jiang L, Bittenbring JT, Huebel K, Schmidt C, Duell J, Metzner B, Krauter J, Glass B, Huettmann A, Schaefer-Eckart K, Silkenstedt E, Klapper W, Hiddemann W, Unterhalt M, Dreyling M, Hoster E; German Lymphoma Alliance (GLA) and the German Low-Grade Lymphoma Study Group (GLSG). Fischer L, et al. Ann Hematol. 2023 Oct;102(10):2791-2801. doi: 10.1007/s00277-023-05385-1. Epub 2023 Aug 8. Ann Hematol. 2023. PMID: 37552322 Free PMC article.
Mantle cell lymphoma (MCL) is a distinct subtype of B-cell lymphoma and commonly used induction immunochemotherapies include the anti-CD20 antibody rituximab. ...
Mantle cell lymphoma (MCL) is a distinct subtype of B-cell lymphoma and commonly used induction immunochemotherapies include the anti …
Rituximab therapy for indolent non-Hodgkin's lymphoma.
Hagenbeek A, Czuczman MS, Ghielmini M, Herold M, Kimby E, Solal-Céligny P, Unterhalt M. Hagenbeek A, et al. Anticancer Drugs. 2002 Nov;13 Suppl 2:S11-7. Anticancer Drugs. 2002. PMID: 12710586 Review.
Rituximab is a specific anti-CD20 chimeric monoclonal antibody against the CD20 antigen, which is stably expressed on most B-cells (from the pre-B-cell stage). Compared with chemotherapy, rituximab has an excellent tolerability profile, making it a good therapeutic …
Rituximab is a specific anti-CD20 chimeric monoclonal antibody against the CD20 antigen, which is stably expressed on most B-cells (f …
[Monoclonal antibody therapy for malignant lymphoma].
Buske C, Dreyling M, Unterhalt M, Hiddemann W. Buske C, et al. Med Klin (Munich). 2005 Jan 15;100(1):14-24. doi: 10.1007/s00063-005-1115-0. Med Klin (Munich). 2005. PMID: 15654538 Review. German.
The treatment options for patients with malignant lymphoma have been substantially enriched by the development of B-cell-specific monoclonal antibodies. One of the reasons for the attractiveness of this approach is the different mode of action of these antibodies compared …
The treatment options for patients with malignant lymphoma have been substantially enriched by the development of B-cell-specific mon …
Transplantation strategies for patients with follicular lymphoma.
Buske C, Dreyling M, Unterhalt M, Hiddemann W. Buske C, et al. Curr Opin Hematol. 2005 Jul;12(4):266-72. doi: 10.1097/01.moh.0000166499.72138.57. Curr Opin Hematol. 2005. PMID: 15928482 Review.
PURPOSE OF REVIEW: This review summarizes the current status and new developments in autologous and allogeneic transplantation strategies for patients with follicular lymphoma including novel concepts of myeloablative radioimmunotherapy, allogeneic transplantation with dose-reduc …
PURPOSE OF REVIEW: This review summarizes the current status and new developments in autologous and allogeneic transplantation strategies fo …
Mantle cell lymphoma: state-of-the-art management and future perspective.
Weigert O, Unterhalt M, Hiddemann W, Dreyling M. Weigert O, et al. Leuk Lymphoma. 2009 Dec;50(12):1937-50. doi: 10.3109/10428190903288514. Leuk Lymphoma. 2009. PMID: 19863180 Review.
Mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphomas (NHL) characterized in almost all cases by the chromosomal translocation t(11;14)(q13;q32) and nuclear cyclin D1 overexpression. ...
Mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphomas (NHL) characterized in almost all cases by the chromos …
Skin Involvement of Mantle Cell Lymphoma May Mimic Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type.
Wehkamp U, Pott C, Unterhalt M, Koch K, Weichenthal M, Klapper W, Oschlies I. Wehkamp U, et al. Am J Surg Pathol. 2015 Aug;39(8):1093-101. doi: 10.1097/PAS.0000000000000445. Am J Surg Pathol. 2015. PMID: 26034867
Mantle cell lymphoma (MCL) is a B-cell neoplasm with a variable and generally aggressive clinical course. ...Lymphomas with these features might be erroneously diagnosed as diffuse large B-cell lymphoma, leg type, if cyclin D1 staining is not performed....
Mantle cell lymphoma (MCL) is a B-cell neoplasm with a variable and generally aggressive clinical course. ...Lymphomas with these fea …
Current status and future perspectives in the treatment of low-grade non-Hodgkin's lymphomas.
Hiddemann W, Unterhalt M. Hiddemann W, et al. Blood Rev. 1994 Dec;8(4):225-33. doi: 10.1016/0268-960x(94)90110-4. Blood Rev. 1994. PMID: 7888829 Review.
The currently available information justifies a conservative approach of observing the natural course of the disease until therapeutic intervention is required due to the occurrence of B-symptoms, hematopoietic insufficiency or lymphoma progression....
The currently available information justifies a conservative approach of observing the natural course of the disease until therapeutic inter …
29 results